Century Therapeutics’ (IPSC) Buy Rating Reaffirmed at Guggenheim

Guggenheim reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a research report sent to investors on Wednesday,Benzinga reports.

Several other equities research analysts have also issued reports on the company. Chardan Capital decreased their target price on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Piper Sandler decreased their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a report on Monday, December 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a research note on Wednesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Century Therapeutics Trading Down 0.7 %

Shares of NASDAQ:IPSC opened at $0.89 on Wednesday. Century Therapeutics has a 1-year low of $0.87 and a 1-year high of $5.51. The stock has a market cap of $75.76 million, a PE ratio of -0.48 and a beta of 1.76. The stock’s fifty day simple moving average is $1.18 and its two-hundred day simple moving average is $1.56.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. During the same period last year, the firm earned ($0.55) earnings per share. On average, sell-side analysts forecast that Century Therapeutics will post -1.63 earnings per share for the current fiscal year.

Institutional Trading of Century Therapeutics

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Century Therapeutics during the 3rd quarter valued at $27,000. Rhumbline Advisers lifted its holdings in shares of Century Therapeutics by 56.0% in the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after buying an additional 18,828 shares in the last quarter. Barclays PLC boosted its position in shares of Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after acquiring an additional 45,797 shares during the period. JPMorgan Chase & Co. grew its stake in Century Therapeutics by 257.6% during the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after acquiring an additional 51,664 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after acquiring an additional 44,155 shares during the period. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.